RxDoctor Payments Data

Joshua Goldberg, DO

Otolaryngology · Willow Grove, PANPI 1962425520

Payments from drug & device makers

$975in general payments, 2019–2025

Across 34 payments — averaging $28.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Optinose US, Inc.$242
  • Intersect ENT, Inc.$177
  • Regeneron Healthcare Solutions, Inc.$172
  • Valeritas, Inc.$114
  • Aerin Medical Inc.$81
  • Neurent Medical Limited$59
  • plus $129 from 3 others

What the payments were for

  • Consulting fees$10010%
  • Food & beverage$87590%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$975 in reported general payments places this provider in the 50th percentile of 456 otolaryngology providers in Pennsylvania.

See all otolaryngology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$388,340
Medicare patients
726
Services billed
8,340

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XhanceFluticasone Propionate12$7,982
Fluticasone Propionate353$4,591
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth27$3,061
SymbicortBudesonide/Formoterol Fumarate13$2,568
Mometasone Furoate23$1,618
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$1,568
Montelukast Sodium175$1,346
Clotrimazole45$911
Nystatin39$839
Ofloxacin43$829
Ipratropium Bromide29$785
Albuterol Sulfate HfaAlbuterol Sulfate34$761
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav65$699
Methylprednisolone138$688
Amoxicillin150$667

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Optinose US, Inc.Xhance$242$7,98212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 456 otolaryngology providers in Pennsylvania.

Other otolaryngology in Willow Grove

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →